New hope for lung scarring: HSK44459 enters final trial phase
NCT ID NCT07519070
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new tablet, HSK44459, for people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. About 420 adults aged 40 and older will receive either the drug or a placebo for 52 weeks. The main goal is to see if the drug helps maintain lung function and reduces flare-ups or hospital stays.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••